These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11723619)

  • 21. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.
    Schneider DJ; Aggarwal A
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of acute central retinal artery occlusionwith the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban.
    Hölschermann H; Krombach C; Jung A; Jacobi F; Tillmanns H; Weinand F
    Thromb Haemost; 2005 Sep; 94(3):684-6. PubMed ID: 16268493
    [No Abstract]   [Full Text] [Related]  

  • 23. [Update on tirofiban].
    Danchin N
    Presse Med; 2001 Jan; 30(2):93-4. PubMed ID: 11244822
    [No Abstract]   [Full Text] [Related]  

  • 24. Should patients with unstable coronary syndromes routinely undergo cardiac catheterization and appropriate revascularization?
    Gazewood J
    J Fam Pract; 2001 Sep; 50(9):739. PubMed ID: 11674901
    [No Abstract]   [Full Text] [Related]  

  • 25. Two i.v. antiplatelet agents marketed for coronary disease.
    Am J Health Syst Pharm; 1998 Jul; 55(14):1440, 1443. PubMed ID: 9676283
    [No Abstract]   [Full Text] [Related]  

  • 26. IIb/IIIa or not IIb/IIIa? That is the question.
    Redwood S
    Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749
    [No Abstract]   [Full Text] [Related]  

  • 27. Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.
    Yang TY; Chang ST; Chung CM; Cheng NJ
    Int Heart J; 2005 Jan; 46(1):139-45. PubMed ID: 15858946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Boersma E; Harrington RA; Moliterno DJ; White H; Simoons ML
    Lancet; 2002 Jul; 360(9329):342-3. PubMed ID: 12147403
    [No Abstract]   [Full Text] [Related]  

  • 29. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Harding SA; Boon NA; Flapan AD
    Lancet; 2002 Jul; 360(9328):256-7. PubMed ID: 12133681
    [No Abstract]   [Full Text] [Related]  

  • 30. Glycoprotein IIb/IIIa antagonists in Takotsubo cardiomyopathy.
    Omar HR
    Herz; 2013 Nov; 38(7):740-2. PubMed ID: 23632423
    [No Abstract]   [Full Text] [Related]  

  • 31. Invasive coronary revascularisation is better than conservative treatment in patients with acute coronary syndromes.
    Gonzi G; Merlini PA; Ardissino D
    Heart; 2001 Oct; 86(4):363-4. PubMed ID: 11559667
    [No Abstract]   [Full Text] [Related]  

  • 32. NICE appraisals and cardiology: glycoprotein IIb/IIIa inhibitors and acute coronary syndromes.
    Hyde T; Knight C
    Hosp Med; 2003 Nov; 64(11):638-9. PubMed ID: 14671871
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass.
    Koster A; Chew DP; Kuebler W; Habazettl H; Bauer M; Hausmann H; Hetzer R; Kuppe H; Hamm CW
    Am J Cardiol; 2003 Feb; 91(3):346-7. PubMed ID: 12565096
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for?
    Davie AP; McMurray JJ
    Eur Heart J; 2002 Jan; 23(1):1-3. PubMed ID: 11741352
    [No Abstract]   [Full Text] [Related]  

  • 35. Platelet glycoprotein IIb/IIIa receptor inhibitors in coronary artery disease.
    Cohen M
    Ann Intern Med; 1996 May; 124(9):843-4. PubMed ID: 8610955
    [No Abstract]   [Full Text] [Related]  

  • 36. Storing paraformaldehyde-fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade: core laboratory considerations.
    Murugesan SR; Gurbel PA; Serebruany VL
    Thromb Res; 1999 Aug; 95(4):201-3. PubMed ID: 10498390
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes.
    Morrow DA; Rifai N; Sabatine MS; Ayanian S; Murphy SA; de Lemos JA; Braunwald E; Cannon CP
    Clin Chem; 2003 Aug; 49(8):1396-8. PubMed ID: 12881457
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic efficiency of tirofiban in acute coronary syndromes.
    Biondi-Zoccai GG; Agostoni P
    Lancet; 2000 Mar; 355(9207):931. PubMed ID: 10752730
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic efficiency of tirofiban in acute coronary syndromes.
    Burnett JR; Blennerhassett J; McConnell W; O'Leary PC; Vasikaran SD
    Lancet; 2000 Mar; 355(9207):929-31. PubMed ID: 10752729
    [No Abstract]   [Full Text] [Related]  

  • 40. Revascularization for everyone?
    Redberg RF
    Eur Heart J; 2005 Mar; 26(5):525; author reply 525. PubMed ID: 15701656
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.